Sanofi dumps Principia Biopharma's San Francisco labs with plans to immediately cut 38 jobs Moderna, AbCellera join forces to tackle major mRNA opportunity Amylyx can proceed with ALS submission to FDA afterall, marking a win for patients’ advocacy efforts Sponsored: Four Steps to Smarter, More Dynamic Deployment Theravance axing 75% of staff, slashing R&D budget after flunking phase 3 Tyra Biosciences banks $173M to bring cancer resistance programs into clinic Haisco to pay $140M to get the ball rolling on Biosplice's phase 3 osteoarthritis drug in China Novo Nordisk Foundation teams up with Broad Institute, Harvard for diabetes, obesity research hub Mesa Labs puts $300M on the table for genetic testing developer Agena Bioscience Newly discovered immune cells block melanoma metastasis in mice and could inspire new treatments Citing 'less-than-optimal' outcomes for Roche's Evrysdi, Biogen launches high-dose Spinraza trial KFF: Systemwide costs of preventable COVID-19 hospitalizations nearly tripled to $5.7B in August Featured Story | By Noah Higgins-Dunn In a one-two punch for Principia Biopharma, Sanofi plans to shutter the company's San Francisco-based drug discovery laboratories by the end of the year and immediately cut 38 jobs, the French pharma told Fierce Biotech. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Moderna’s early vision, years before it became synonymous with COVID-19 vaccines, was to “enable the body to produce its own healing proteins.” Infectious disease and cancer vaccines later rose up the list of priorities at Moderna, but work on the original plan continued—and is now getting a boost through a pact with the industry’s go-to antibody shop AbCellera. read more By Annalee Armstrong The FDA has done a U-turn on Amylyx’s amyotrophic lateral sclerosis (ALS) drug AMX0035. After asking for a new phase 3 study in April, the agency will now accept the biotech’s submission based on phase 2 evidence. read more Sponsored by: IQVIA Are you using data and analytics to design smarter campaigns and more effective sales rep deployment? read more By Nick Paul Taylor Theravance Biopharma’s rotten run has triggered big changes at the biotech. With a phase 3 rare disease study becoming the third trial to fail in as many months, Theravance is axing 75% of its staff and narrowing its focus to respiratory diseases. read more By Amirah Al Idrus Tyra Biosciences is the latest biotech to rake in an upsized IPO. Its $172.8 million deal will push three programs targeting drug-resistant cancers into the clinic. The company will start trading on the Nasdaq under the ticker “TYRA” on Wednesday. It expects the funds to support its work through at least 2024, according to a securities filing. read more By Kyle LaHucik Haisco Pharmaceutical will pay Biosplice Therapeutics $140 million to license the San Diego biotech's knee osteoarthritis drug candidate. Haisco also snags rights to the treatment, lorecivivint, for other musculoskeletal conditions in China. read more By Ben Adams The Novo Nordisk Foundation, part of the Danish pharma Novo Group, is stumping up $47.5 million for a new research collab between the Broad Institute of MIT and Harvard. read more By Andrea Park Within the first year of the buyout, Mesa said it expects Agena to bring in between $63 million and $67 million in revenue, plus an additional $3 million to $5 million in COVID testing revenue. read more By Arlene Weintraub A research team led by Dartmouth discovered T cells in the lymph nodes that stay put and have the power to kill melanoma cells before they can spread. They believe that as they build their understanding of how the cells work, they may find new therapeutic methods for preventing metastasis. read more By Eric Sagonowsky While much of the attention on Biogen lately has centered on its launch of controversial Alzheimer's drug Aduhelm, the company is also feeling the heat from a new challenger in spinal muscular atrophy. After analyzing data around its rival, Biogen has unveiled plans to run a high-dose trial for its drug in patients who've had prior treatment with Evrysdi. read more By Dave Muoio The Kaiser Family Foundation estimated there were 287,000 vaccine-preventable COVID-19 hospitalizations from June to August, with nearly two-thirds of that burden coming in the last month alone. read more | | The life-changing potential of cell & gene therapy demands lab services that are just as transformative. LabConnect® leads the evolution of lab services with customized solutions that simplify clinical trial complexity. Let us help with your next study so you can focus on the research. Learn more. |
Resources Sponsored By: Unlearn AI Read Unlearn’s whitepaper to learn about how novel trial designs with Digital Twins enable more efficient clinical trials, with higher power and smaller required sample sizes. Sponsored by: Patheon by Thermo Fisher Scientific Choose the right AAV platform for your viral vector-based therapy Sponsored by: XIFIN inc. Download the Value of Precision Medicine Informatics (PMI) Initiatives report to learn about the technology, data types, and the value derived from more than 100 PMI initiatives. Sponsored by: EVERSANA Today’s economics do not allow manufactures to keep making decisions in an antiquated way. They need to challenge tradition & deliver faster, cheaper, successful launches. Learn how. Sponsored by: Thermo Fisher Scientific Thermo Fisher Scientific introduces a new NK cell culture medium designed to support feeder-free, high-yield growth for cell therapy applications. Sponsored by: Cascade Chemistry by Aceto Read four customer success stories and four success factors that helped move pharmaceutical customers of Cascade Chemistry by Aceto quickly and effectively to clinic with trial-ready APIs. Sponsored by: ConnectiveRx Topple barriers to getting patients started on therapy. Guide them with mobile. Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Medical Affairs Strategic Summit (MASS) September 13-15, 2021 | New Brunswick, NJ Let A Digital Sherpa Uncomplicate The Path for Patients Wednesday, September 15 | 1 PM ET Sea-dumped chemical weapons: environmental risk, occupational hazard September 22, 2021 1pm EST The MedTech Conference 2021 September 27 - 30, 2021 Clinical Quality Oversight Forum September 27-29, 2021 | Philadelphia, PA Introduction to Structure Elucidation in Drug Development Sep 29, 2021 1 pm EST Pharma PR & Communications Summit October 4-5, 2021 | Jersey City, NJ Virtual U.S. Healthcare Compliance Certificate Program October 11 – 14, 2021 Fierce Biotech Cell & Gene Therapy October 19, 2021 | Virtual Event Fierce Health Payer Summit October 26, 2021 | Virtual Event Announcing the 9th International mRNA Health Conference November 09-10, 2021 | Mercure MOA Berlin & Online Diversity, Equity & Inclusion Week November 9–11, 2021 | Virtual Event Drug Development Boot Camp® 2021 Onsite and VIRTUAL in real time November 17-18, 2021 | Register now! Pre-Boot Camp preparation is now available. Fierce Biotech Forum 2022 | Virtual Event | 